ALS in Focus: The Challenges Are Well Documented. What Happens Next?

Canada’s Drug Agency (CDA) has released its final ALS in Focus: Canada’s Systems for ALS Care and Support report, providing a comprehensive national assessment of the barriers facing Canadians affected by ALS.

For people living with ALS and their families, the findings are not new. Lengthy diagnostic delays, unequal access to specialized care and treatments, and the significant burden placed on caregivers are challenges they have experienced and raised for years.

ALS Action Canada is calling for meaningful action following the release of Canada’s Drug Agency’s final assessment of ALS care and support — a report shaped in part by the contributions of three of our Members and documenting challenges long familiar to people living with ALS and their caregivers.

The report brings these realities together in a national assessment. For ALS Action Canada, the priority now is ensuring that this work leads to meaningful improvements in care, treatment access and support.

Bringing patient and caregiver voices to the assessment

Two ALS Action Canada Board Directors, Cali Orsulak and Rick Zwiep, along with Advocacy Committee member Dr. Andrew Darke, served on the report’s Advisory Group, bringing patient, caregiver and clinical perspectives to the project.

Their contributions included three meetings with CDA’s project team and extensive feedback on hundreds of pages of draft materials.

This substantial volunteer commitment reflects ALS Action Canada’s belief that people with lived experience must have a meaningful role in the processes that shape healthcare decisions.

We appreciate the opportunity to contribute to this national initiative and recognize the work undertaken by CDA to document the current state of ALS care and support in Canada.

What the report confirms

The findings reinforce several longstanding challenges facing Canadians affected by ALS:

  • Lengthy diagnostic delays: Registry data indicate an average of 15 months between symptom onset and diagnosis, with longer delays in rural communities.
  • Unequal access to care and treatment: Access to specialized ALS clinics, medications, equipment and supportive services varies across Canada.
  • Significant caregiver burden: Families frequently face fragmented healthcare services, complex care coordination responsibilities and substantial out-of-pocket expenses.

These findings provide further evidence of the challenges that patients, caregivers and advocates have been raising for years.

From documenting challenges to driving change

While ALS in Focus provides a comprehensive picture of ALS care and support across Canada, it does not set out specific recommendations for addressing the challenges identified.

For ALS Action Canada, this distinction matters.

Documenting the challenges is an important step, but meaningful progress will depend on how governments, healthcare organizations and other decision-makers respond to the findings.

The question now is not whether these barriers exist, but what will be done to address them.

ALS Action Canada will continue advocating for patient and caregiver perspectives to inform decisions about care, treatment access and healthcare policy.

The report provides an important foundation. Turning its findings into meaningful improvements for Canadians affected by ALS must be the next step.

Read the full ALS in Focus report from Canada’s Drug Agency

Facebook
LinkedIn

Explore more

Bringing the ALS Patient Perspective to Canada’s Drug Policy Reform Debate

ALS Action Canada Member Dr. Andrew Darke, who is living with ALS, is contributing to the national debate on drug policy reform. In a Financial Post commentary with Nigel Rawson and John Adams, he examines how recent U.S. trade policies strengthen the case for reforms to Canada’s drug approval, pricing and coverage processes. For ALS Action Canada, advocating for timely and equitable access to innovative treatments remains a key priority.

Read More »

A Patient Perspective on ALS Clinical Trials and Timely Access

How much evidence should be required before people living with ALS can access a promising new therapy?

In a newly published Reader Response in Neurology, Dr. Andrew Darke, an ALS Action Canada Advocacy Committee Member, responds to a recent article examining what its authors describe as a “credibility gap” in ALS clinical trials, due to what it describes as a “Clinical Trial Industrial Complex” involving ALS neurologists and manufacturers of new drugs for ALS.

Read More »